Taurolidine: A novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines

Investigational New Drugs

Volumn 25, Issue 4, 2007, Pages 305-312

  Walters, Denise K ^a   Muff, Roman ^a   Langsam, Bettina ^a   Gruber, Philipp ^a   Born, Walter ^a   Fuchs, Bruno ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Chemotherapy; Osteosarcoma; Taurolidine

Indexed keywords

CASPASE; DOXORUBICIN; TAUROLIDINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE CELL; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENCY; GENETIC DISORDER; HUMAN; HUMAN CELL; MONOTHERAPY; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; HUMANS; OSTEOSARCOMA; TAURINE; THIADIAZINES;

EID: 34250639033     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9052-9     Document Type: Article

References (26)

1. Friedman MA, Cater S (1972) The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol 4:482-510
2. Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422-441
3. Browne MK, MacKenzie M, Doyle PJ (1978) Controlled trial of taurolidine in established bacterial peritonitis. Surg Gynecol Obstet 146:721-724
4. Billing A, Frohlick D, Ruckdeschel G (1992) Der Einfluss von Taurolidine aud die korpereigene Abwehr und die Keimelimination bei der menschlichen Peritonitis. Langenbecks Arch Chir 377:180-185
5. Bohm B, Schwenk W, Muller JM (1998) Long-term results after laparoscopic resection of colorectal carcinoma. Chirurg 70:453-455
6. Knight BI, Skellern GG, Browne MK, Pfirrmann RW (1981) Peritoneal absorption of the antibacterial and antiendotoxin taurolidine in peritonitis. Br J Clin Pharmacol 12:695-699
7. Gidley MJ, Sanders JK, Myers ER, Allwood MC (1981) The mode of antibacterial action of some "masked" formaldehyde compounds. FEBS Lett 127:225-227
8. Gorman SP, McCafferty DF, Woolfson AD, Jones DS (1987) Electron and light microscope observations of bacterial cell surface effects due to taurolidine treatment. Lett Appl Microbiol 4:103-109
9. Gorman SP, McCafferty DF, Woolfson AD, Jones DS (1987) Reduced adherence of micro-organisms to human epithelial cells following treatment with Taurolidine, a novel antimicrobial agent. J Appl Bacteriol 62:315-320
10. Calabresi P, Goulette FA, Darnowski JW (2001) Taurolidine: cytotoxic and mechanistic evaluation of a novel anti-neoplastic agent. Cancer Res 61:6816-6821
11. McCourt M, Wang JH, Sookhai S, Redmond HP (2000) Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol 7:685-691
12. Rodak R, Kubota H, Ishihara H, Eugster HP, Konu D, Mohler H, Yonekawa Y, Frei K (2005) Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vacular endothelial growth factor production by taurolidine. J Neurosurg 102:1055-1068
13. Shrayer DP, Lukoff H, King T, Calabresi P (2003) The effect of Taurolidine on adherent and floating subpopulations of melanoma cells. Anti-cancer Drugs 14:295-303
14. Nici L, Monfils B, Calabresi P (2004) The effects of Taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res 10:7655-7661
15. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M (2004) Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res 24:1143-1147
16. Hellwinkel OJ, Muller J, Pollmann A, Kabisch H (2005) Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes. J Gene Med 7:407-419
17. Boersma HH, Kietselaer B, Stolk L, Bennaghmouch A, Hofstra L, Narula J, Heidendal G, Reutelingsperger C (2005) Past, present, and future of Annexin A5: from protein discovery to clinical applications. J Nucl Med 46:2035-2050
18. Nestler G, Schulz U, Schubert D, Krüger S, Lippert H, Pross M (2005) Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats. Surg Endosc 19:280-284
19. Conlan AA, Abramor E, Delikaris P, Hurwitz SS (1983) Taurolidine instillation as therapy for empyema thoracis. A prospective study of 50 patients. S Afr Med J 64:653-655
20. Browne MK (1981) The treatment of peritonitis by an antiseptic-taurolin. Pharmatherapeutica 2:517-522
21. Buhler HU, Mikic S, Wicki O (1978) A new surgical lavage. Helv Chir Acta 45:143-145
22. Jacobi CA, Menenakos C, Braumann C (2005) Taurolidine-a new drug with anti-tumor and anti-angiogenic effects. Anti-cancer Drugs 16:917-921
23. Darnowski J, Goulette FA, Cousens LP, Chatterjee D, Calabresi P (2004) Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol 54:249-258
24. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2:563-572
25. Link MP, Eilber F (1989) Pediatric oncology: osteosarcoma. In: Pizzo PS, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott, Philadelphia, pp 689-711
26. Meyers PA, Gorlick R (1997) Osteosarcoma. Pediatr Clin N Am 44:973-989